GI Dynamics raises $34.3m for EndoBarrier trial
05 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has raised $34.3m through a placement round to help fund its US phase II trial and other commercialisation efforts for EndoBarrier, its obesity and type 2 diabetes treatment.
QRxPharma replaces CEO after MoxDuo setback
02 May, 2014 by Dylan Bushell-EmblingQRxPharma's (ASX:QRX) long-serving CEO Dr John Holday has stepped down and been replaced by COO Dr Edward Rudnic, following its latest regulatory setback for dual-opioid drug Moxduo.
Fibrotech bought by Shire for at least $81m
02 May, 2014 by Dylan Bushell-EmblingMelbourne-based biopharma Fibrotech has agreed to be bought out by Shire for an initial US$75 million ($80.9 million). The deal will also involve development and regulatory milestone payments.
CardioCel calcification-free after six years: Admedus
01 May, 2014 by Dylan Bushell-EmblingThe six-year follow-up for the first patient enrolled in a phase II trial of Admedus's CardioCel tissue patch has detected no calcification issues or complications.
Mesoblast seeks FDA fast-track for GVHD treatment
01 May, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) will soon meet with the US FDA to discuss ways to accelerate the approval process for Prochymal, a stem cell-based treatment bought from Osiris Therapeutics, in GVHD.
STA to distribute Iluvien in A/NZ
29 April, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has become the exclusive distributor in ANZ for Iluvien, a DMO treatment being commercialised by Alimera Sciences under licence from pSivida (ASX:PVA).
BioBusiness Asia Conference calls for presenting proposals
29 April, 2014The 2014 BioBusiness Asia Conference, this year combined with BioTaiwan Exhibition 2014 to enlarge the partnering candidate pool, is calling for proposals from companies interested in presenting.
Cell Therapies names new CEO
28 April, 2014 by Dylan Bushell-EmblingCell Therapies has selected Dr Tim Oldham to become its new CEO to help drive the company's South-East Asian growth strategy.
Phosphagenics completes enrolment in acne trial
24 April, 2014 by Dylan Bushell-EmblingPhosphagenics has completed enrolment for a phase II trial of an acne treatment candidate that uses its TPM transdermal drug delivery technology.
QRxPharma faces third FDA knockback for Moxduo
24 April, 2014 by Dylan Bushell-EmblingAn FDA advisory committee has recommended against approving QRxPharma's (ASX:QRX) third NDA for dual-opioid pain relief product Moxduo IR.
Export study reveals barriers for Australian companies
24 April, 2014The most comprehensive export survey of its type, Australia's International Business Survey, was conducted to understand and highlight the major issues facing exporters.
Analytica launches $3m capital raising
23 April, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) is raising up to $3m through a placement and entitlement offer to help accelerate its marketing efforts for female urinary incontinence treatment device PeriCoach.
ResMed launches two new AirFit masks
22 April, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has added a new nasal mask and a full-face mask to its AirFit line of sleep-disordered breathing therapy devices.
AusBiotech to submit to Senate's 'Australian innovation system' inquiry
22 April, 2014AusBiotech is preparing a submission following the Senate's referral of an inquiry into Australia's innovation system to the Senate Economics References Committee for inquiry and report.
Drawbridge anaesthetic beats propofol during trial
17 April, 2014 by Dylan Bushell-EmblingDrawbridge Pharmaceuticals announced that anaesthesia candidate Phaxan outperformed the SOC propofol during the first in-human trial comparing the two drugs.
